Phase II Study of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of Lutetium LU 177 (Lutathera) dotatate in comparison with capecitabine and temozolomide in patients with advanced pancreatic neuroendocrine tumors.
General Information
NCT#: NCT05247905
Study ID: A022001
Trial Phase: Phase II
Trial Sponsor: Alliance for Clinical Trials in Oncology
Therapies Used in This Trial: Capecitabine, Temozolomide, lutetium Lu 177 dotatate